medigraphic.com
Federación Mexicana de Ginecología y Obstetricia, A.C.

2011, Número 12

<< Anterior Siguiente >>

Ginecol Obstet Mex 2011; 79 (12)


Prevención secundaria (detección) del cáncer cervicouterino

Idioma: Español
Referencias bibliográficas: 56
Paginas: 808-815
Archivo PDF: 197.30 Kb.


FRAGMENTO

El cáncer cervicouterino es una enfermedad prevenible pero para ello los países deben contar con programas de detección bien organizados que aseguren una cobertura cercana a la universal y un desempeño general de muy alta calidad. De otra manera, sus resultados serán deficientes. El objetivo de dichos programas es encontrar, diagnosticar y tratar la lesión precursora de la enfermedad, esto es, la lesión escamosa intraepitelial de alto grado (LEIAG) así como ejercer, posteriormente, vigilancia epidemiológica de las mujeres tratadas.


REFERENCIAS (EN ESTE ARTÍCULO)

  1. Guzick DS. Efficacy of screening for cervical cancer: A review. Amer J Publ Health1978;68:125-134.

  2. Lazcano-Ponce EC, Moss S, Alonso de Ruiz P, et al. Cervical cancer screening in developing countries: why is it ineffective? The case of Mexico. Arch Med Res 1999;30:240-250.

  3. Wright TC Jr. Cervical cancer screening in the 21st century: Is it time to retire the PAP smear? Clin Obstet Gynecol 2007;50:313-323.

  4. Stoler ME, Gaffikin L, Blumenthal PD. Cervical cancer screening in developing countries. Prim Care Update Ob/Gyns 2000;7:118-123.

  5. Heideman DAM, Snijders PJF, Berkhof J, et al. Vaccination against HPV: indications for women and the impact on the cervical screening program. BJOG 2008;115:938-946

  6. Harper DM. Currently approved prophylactic HPV vaccines. Expert Rev Vaccine 2009;8:1663-1679.

  7. Bosch FX, de Sanjosé S, Miralles C, et al. La prevención del precáncer y del cáncer cervical en España: nuevas opciones para el Siglo XXI. Folia Clin Obstet Ginecol 2010;81:6-24.

  8. Sanjose S, Quint WGV, Alemany L, et al. Human papillomavirus genotype attribution in invasive cervical cancer: a retrospective cross-sectional worldwide study. Lancet Oncol 2010;11:1048-1056.

  9. Dillner J, Arbyn M, Dillner L. Translational mini-review series on vaccines: monitoring of human papillomavirus vaccination. Clin Exp Immunol 2007;148:199-207.

  10. Sankaranarayanan R, Nene BM, Shastri SS, et al. HPV screening for cervical cancer in rural India. New Engl J Med 2009;360:1385-1394.

  11. Laara E, Day NE, Hakama M. Trends in mortality from cervical cancer in the Nordic countries: association with organized screening programs. Lancet 1987;1:1247-1249.

  12. Denny L, Quinn M, Sankaranarayanan R. Capítulo 8: El cribado del cáncer de cuello uterino en los países en vías de desarrollo. Vaccine 2006;24(Supl 3):S76-S83.

  13. Reinshaw AA. A practical problem with calculating the false–negative rate of Papanicolaou smears interpretation by rescreening negative cases alone. Cancer 1999;87:351-353.

  14. Tabares SB de N, Alves de Sousa NL, Manrique EJC, et al. Comparison of the performance of rapid rescreening. 10% random review and clinical risk criteria as methods of internal quality control in cervical cytopathology. Cancer Cytopathol 2006;114:165-170.

  15. Córdoba RS, Olivares MAK, Robles SS, y col. Revisión rápida como control de calidad interna en citología cérvico-vaginal. Rev Med Hosp Gral 2005;68:213-217.

  16. Lazcano-Ponce E, Nájera P, Buiatti E, et al. The cervical cancer-screening program in Mexico. Problems with access and coverage. Cancer Causes Control 1997;8:698-704.

  17. Sawaya GF, Grimes DA. New technology in cervical cytology screening: A word of caution. Obstet Gynecol 1999;94:307-310.

  18. Arbyn M, Bergeron CH, Klinkhamer P, et al. Liquid compared with conventional cervical cytology. A systematic review and meta-analysis. Obstet Gynecol 2008;111:167-177.

  19. Siebers GA, Klinkhamer PJJM, Grefte JMM, et al. Comparison of liquid -based cytology with conventional cytology for detection of cervical cancer precursors. A randomized controlled trial. JAMA 2009;302:1757-1764.

  20. Castle PE, Fetterman B, Poitras N, et al. Five-year experience of Human Papilloma Virus DNA and Papanicolaou cotesting. Obstet Gynecol 2009;113:595-600.

  21. Berkovitz Z, Saraiya M, Bernard V, et al. Common abnormal results of Pap and Human Papillomavirus cotesting. Obstet Gynecol 2010;116:1332-1340.

  22. Schiffman M, Herrero R, Hildesheim A, et al. HPV DNA testing in cervical cancer screening. Results from women in a high-risk province of Costa Rica. JAMA 2000;283:87-93.

  23. Mandelblatt JS, Lawrence WF, Womack AM, et al. Benefits and costs of using HPV testing to screen for cervical cancer. JAMA 2002;287:2372-2381.

  24. Cuzick J, Arbyn M, Sankaranarayanan R, et al. Overview of human papilloma virus-based and other novel options for cervical cancer screening in developed and developing countries. Vaccine 2008;26(S10):K29-K41.

  25. Wright TC Jr, Denny L, Kuhn L, et al. HPV DNA testing of selfcollected vaginal samples compared with cytologic screening to detect cervical cancer. JAMA 2000;283:81-86.

  26. Salmerón J, Lazcano-Ponce E, Lorincz A, et al. Comparison of HPV-based assay with Papanicolaou smears for cervical cancer screening in Morelos, Mexico. Cancer Causes and Control 2003;14:505-512.

  27. Norma Oficial Mexicana NOM-014-SSA2-1994. Para la prevención, detección, diagnóstico, tratamiento, control y vigilancia epidemiológica del cáncer cérvico uterino Diario Oficial de la Federación 31 de mayo de 2007.

  28. Watson M, Saraiya M, Bernard V, et al. Burden of cervical cancer in the United States, 1998-2003. Cancer 2008;113:2855-2864.

  29. Waxman AG. Guidelines for cervical cancer screening: History and scientific rationale. Clin Obstet Gynecol 2005;48:77-97.

  30. Bosch FX, de Sanjosé S, Miralles C, et al. La prevención del precáncer y del cáncer cervical en España: nuevas opciones para el siglo XXI. Folia Clin Obstet Ginecol 2010;81:6-24.

  31. Guido RS, Jeronimo J, Schiffman M, et al. The distribution of neoplasia arising on the cervix: Results from the ALTS trial. Am J Obstet Gynecol 2005;193:1331-1337.

  32. Solomon D, Davey D, Kurman R, et al. The 2001 Bethesda System. Terminology for reporting results of cervical cytology. JAMA 2002;287:2114-2119.

  33. INEGI. Instituto Nacional de Estadística, Geografía e Informática. http://www.inegi.org.mx/Sistemas/. Consultado el 23/02/2011

  34. Wright TC Jr, Schiffman M. Adding a test for human papillomavirus DNA to cervical-cancer screening. N Engl J Med 2003;348:489-490.

  35. Schiffman M, Castle PE. The promise of global cervical-cancer prevention. N Engl J Med 2005;353:2101-2104.

  36. Schmeink CE, Massuger LF, Lenselink CH, et al. Effect of the menstrual cycle and hormonal contraceptives on human papillomavirus detection in young unscreened women. Obstet Gyneol 2010;116:67-75.

  37. Castle PE, Rodriguez AC, Porras C, et al. A comparison of cervical and vaginal human papillomavirus. Sex Trasm Dis 2007;34:849-855.

  38. Wright TC Jr, Schiffman M, Solomon D, et al. Interim guidance for the use of human papillomavirus DNA testing as an adjuvant to cervical cytology screening. Obstet Gynecol 2004;103:304-309.

  39. Muñoz N, Bosch FX, Castellsagué X, et al. Against which Human Papillomavirus types shall we vaccinate and screen? The international perspective. Int J Cancer 2004;111:278-285.

  40. Castle PE, Schiffman M, Wheeler CM, et al. Hybrid capture 2 viral load and the 2-year cumulative risk of cervical intraepithelial neoplasia grade 3 or cancer. Am J Obstet Gynecol 2004;191:1590-1597.

  41. Franco EL, Cuzik J, Hildesheim A, et al. Capítulo 20: Planificación del cribado del cáncer del cuello uterino en la era de la vacunación contra el VPH. Vaccine 2006;24(S3):S188-S195.

  42. Markowitz LE, Unger ER, Saraiya M. Primary and secondary prevention of cervical cancer: Opportunities and challenges. J Natl Cancer Inst 2009;101:439-440.

  43. Follen Mitchell M, Schottenfeld D, Tortolero-Luna G , et al. Colposcopy for the diagnosis of squamous intraepithelial neoplásica: A metaanalysis. Obstet Gynecol 1998;91:626-631

  44. Cantor SB, Cárdenas-Turanzas M, Cos DD , et al. Accuracy of colposcopy in the diagnostic setting compared with the screening setting. Obstet Gynecol 2008;111:7-14

  45. Orbell S, Crombie I, Robertson A , et al. Assessing the effectiveness of a screening campaign: who is missed by 80% cervical screening coverage? J R Soc Med 1995;88:389-394

  46. Adab P, McGhee SM, Yanova J , et al. Effectiveness and efficiency of opportunistic cervical cancer screening. Comparison with organized screening. Med Care 2004;42:600-609

  47. Sandella JA. Quality assurance practice in a Colposcopy Clinic. Clin Conult Obstet Gynec 1994;6:89-97

  48. Madrigal de la Campa MA, Lazcano Ponce EC, Infante CC. Sobreutilización del servicio de colposcopía en México. Ginec Obstet Mex 2005;73:637-647

  49. Soutter WP, de Barros Lopes A, Fletcher A , et al. Invasive cervical cancer after conservative therapy for cervical intraepithelial neoplasia. Lancet 1997;349:978-980

  50. Schiffman M. When to test women for human papillomavirus. BMJ 2006;332:61-62

  51. Coupé VMH, Berkof J, Verheijen RHM , et al. Cost-effectiveness of human papillomavirus testing after treatment for cervical intraepithelial neoplasia. BMJ 2007;114:416-424

  52. Strander B, Andersson-Ellström A, Milson I , et al. Long term risk of invasive cancer after treatment for cervical intraepithelial neoplasia grade 3: population based cohort study. BMJ 2007;335:1077-

  53. Jakobson M, Gissler M, Paavonen J , et al. Long-term mortality in women treated for cervical intraepithelial neoplasia. BJOG 2009;116:838-844

  54. Elfgren K, Jacobs M, Walboomers JM , et al. Rate of human papillomavirus clearance after treatment of cervical intraepithelial neoplasia. Obstet Gynecol 2002;100:965-971

  55. Damasus-Awatai G, Freeman-Wang T. Human papillomavirus and cervical screening. Curr Opn Obstet Gynecol 2003;15:473-477

  56. Arbyn M, Paraskevaidis E, Martin-Hirsch P , et al. Clinical utility of HPV-DNA detection: triage of minor cervical lesions, followup of women treated for high-grade CIN. An update of pool.




2020     |     www.medigraphic.com